{"schema_version":"secwatch.filing_event.v1","accession":"0001072613-23-000453","form_type":"8-K","ticker":"NTIP","cik":"0001065078","company_name":"NETWORK-1 TECHNOLOGIES, INC.","filed_at":"2023-09-06T23:59:59+00:00","discovered_at":"2026-05-14T18:03:33.055098+00:00","generated_at":"2026-06-10T23:13:11.889324+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Network-1's investee ILiAD reports positive Phase 2b results for pertussis vaccine BPZE1","bullets":["ILiAD's BPZE1 intranasal vaccine met primary endpoint protecting against B. pertussis colonization (p=0.03) in CHAMPION-1 study.","Vaccine reduced B. pertussis bacterial burden by 98.0% compared with placebo; no serious adverse events.","Network-1 holds ~6.8% stake in ILiAD from $7M investment.","ILiAD plans to present full data at World Vaccine Congress on Oct 19, 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001072613-23-000453","json":"https://secwatch.observer/filing/0001072613-23-000453.json","markdown":"https://secwatch.observer/filing/0001072613-23-000453.md","text":"https://secwatch.observer/filing/0001072613-23-000453.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1065078/000107261323000453/0001072613-23-000453-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1065078/000107261323000453/form8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T23:13:11.889324+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}